|From: SpecGuru (Rep: 63) reply to SpecGuru||Date: 09/13/2016 15:27|
|Forum: Keryx Biopharmaceuticals - Msg #2600||Thread #673868708 (Rec: 0) |
|Strong in this bloody market. Production resuming, sNDA, IDA filing, Bought-out, etc. coming in the next few months touching $5 Billion market. Expecting double digit market cap.|
"...Keryx (NASDAQ:KERX) reported top-line results from its pivotal Phase 3 study that was intended to provide the basis for a label expansion of Auryxia. With these positive results, the company now intends to file a supplemental new drug application in the third quarter of 2016 seeking to expand Auryxia's indication to iron deficiency anemia.
IDA is a common complication of chronic kidney disease. Approximately, 1.6 million people living in the U.S. with stage 3-5 non-dialysis dependent chronic kidney disease (NDD-CKD) suffer from IDA. If Auryxia will be approved for the treatment of IDA in these patients, it would be the only FDA-approved iron treatment in a tablet form available to these patients...."
Re: I should say it has all short term, intermediate term and long term catalysts...
*****I am writing drunk*****
| Reply to SpecGuru - Msg #2599 - 09/12/2016 15:11|
I should say it has all short term, intermediate term and long term catalysts. Re: Flirting $7.00.
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.